Try our Advanced Search for more refined results
Life Sciences
- 
									October 06, 2025
									2 Firms To Lead Humana Investor Suit Over Post-COVID CostsGlancy Prongay & Murray LLP and The Rosen Law Firm will co-lead consolidated shareholder derivative claims against healthcare giant Humana Inc. alleging its brass made the company downplay the "pent-up demand" that pushed up patient utilization rates on the heels of the COVID-19 pandemic. 
- 
									October 06, 2025
									Neuriva 'Brain Health' Products Don't Work, Class Suit ClaimsA proposed class of buyers sued Reckitt Benckiser LLC in Illinois federal court on Monday, alleging its Neuriva line of products make promises about supporting brain health that they come nowhere near delivering. 
- 
									October 06, 2025
									Law Profs Say CareDx False Ad Verdict Should StandTwo law professors have urged the Third Circuit to grant medical testing company CareDx's request for another chance to argue why its $45 million false advertising verdict against a rival should be reinstated, saying a ruling nixing the verdict will disallow juries from using circumstantial evidence and encourage false advertisers to "try their luck." 
- 
									October 06, 2025
									3rd Circ. Rejects Novo Nordisk's Medicare Pricing ChallengeThe Third Circuit on Monday shot down another challenge to the Medicare drug price negotiation program, denying claims by pharmaceutical giant Novo Nordisk that Congress illegally delegated too much authority to the executive branch. 
- 
									October 06, 2025
									Hagens Berman Fights Sanctions Over Thalidomide SuitsPlaintiffs firm Hagens Berman Sobol Shapiro LLP strenuously denied claims that it should be sanctioned for filing since-dropped product liability cases, responding to a judge's show cause order by saying it spent hundreds of hours researching the legal theories it pursued before filing the cases and devoted substantial time and resources to them. 
- 
									October 06, 2025
									Cooley Adds Life Sciences Trio From WilmerHale, SidleyCooley LLP announced Monday that it is boosting its life sciences bench with a bicoastal trio of partners from WilmerHale and Sidley Austin LLP. 
- 
									October 06, 2025
									High Court Turns Down 6 Patent Cases At Start Of TermThe U.S. Supreme Court on Monday rejected six petitions in patent-related cases, taking some of its first actions on intellectual property matters this term. 
- 
									October 06, 2025
									Justices Won't Review Blacklisting Case Against LegitScriptThe U.S. Supreme Court refused Monday to review a bid from LegitScript to duck an antitrust case accusing it of blacklisting a drug price checking website despite contentions that it facilitates illegal imports of prescription drugs. 
- 
									October 03, 2025
									Up First At High Court: Election Laws & Conversion TherapyThe U.S. Supreme Court will hear oral arguments in six cases during the first week of its October 2025 term, including in disputes over federal candidates' ability to challenge state election laws, Colorado's ban on conversion therapy, and the ability of a landlord to sue the U.S. Postal Service for allegedly refusing to deliver mail. 
- 
									October 03, 2025
									4 Top Supreme Court Cases To Watch This TermAfter a busy summer of emergency rulings, the U.S. Supreme Court will kick off its October 2025 term Monday with only a few big-ticket cases on its docket — over presidential authorities, transgender athletes and election law — in what might be a strategically slow start to a potentially momentous term. Here, Law360 looks at four of the most important cases on the court's docket so far. 
- 
									October 03, 2025
									Few Petitions Move Forward In Newest Discretion ReviewsDeputy U.S. Patent and Trademark Office Director Coke Morgan Stewart rejected 15 Patent Trial and Appeal Board petitions Friday night, but allowed five challenges to proceed. 
- 
									October 03, 2025
									6th Circ. Will Hear Ohio PBM Fight Arguments In DecemberThe Sixth Circuit will hear arguments from the state of Ohio and the pharmacy benefit managers it's accusing of colluding to raise the price of prescription medications in December to decide whether the matter belongs in state or federal court. 
- 
									October 03, 2025
									Zynex Investors Seek To Merge, Stay Insider Trading SuitsZynex shareholders who accused company executives of inflating stock prices to cash out on shares asked a Colorado federal judge on Friday to consolidate and temporarily pause their derivative suits to wait and see how a related proposed securities class action involving significant similar facts and circumstances plays out. 
- 
									October 03, 2025
									NIH Sets Patent License Policy Aimed At Promoting AccessThe National Institutes Of Health has implemented a new policy that was proposed during the Biden administration to require those seeking commercial licenses to NIH-owned patents to detail how they will promote patient access for new drugs or medical devices they develop. 
- 
									October 03, 2025
									2nd Circ. Erases Injunction In Pet Supplement False Ad FightThe Second Circuit on Friday undid a lower court order blocking Zesty Paws from billing itself in ads as the top U.S. pet supplement brand, saying it didn't apply the proper standard correctly. 
- 
									October 03, 2025
									Benzene At NC BASF Plant Caused Cancer, Ex-Worker SaysA former worker at a North Carolina vitamin plant is suing BASF Corp. and affiliates of Takeda America Holdings Inc. in North Carolina federal court, alleging BASF exposed her to benzene, resulting in her developing cancer later in life. 
- 
									October 03, 2025
									The Roberts Court At 20: How The Chief Is Reshaping AmericaTwenty years after John Roberts became the 17th chief justice of the United States, he faces a U.S. Supreme Court term that's looking transformative for the country and its institutions. How Justice Roberts and his colleagues navigate mounting distrust in the judiciary and set the boundaries of presidential authority appear increasingly likely to define his time leading the court. 
- 
									October 03, 2025
									Stryker Gets Fed. Circ. To Ax Bone Fusion Patent ClaimsThe Federal Circuit on Friday reversed the Patent Trial and Appeal Board's findings that Stryker failed to show that certain claims were anticipated in a trio of OsteoMed patents relating to ways to secure bones together. 
- 
									October 02, 2025
									PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy'The Patent Trial and Appeal Board has ended Amgen Inc.'s challenge to a now-disclaimed patent covering Bristol-Myers Squibb Co.'s blockbuster cancer drug Opdivo, and denied Bristol-Myers' request to pursue a replacement patent. 
- 
									October 02, 2025
									FDA OKs New Generic Abortion Pill, Drawing Conservative IreThe U.S. Food and Drug Administration has approved a second generic version of the abortion medication mifepristone, prompting outrage from anti-abortion groups and conservative politicians. 
- 
									October 02, 2025
									Feds Eye Partial Pretrial Ruling In Regeneron FCA CaseThe government has urged a Massachusetts federal judge to rule that Regeneron Pharmaceuticals "naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it does not need to prove the tougher "but-for causation" standard for its theory of false certification. 
- 
									October 02, 2025
									NC Chief Judge Scolds Medical Supply Co.'s 'Rude' DemandA North Carolina federal judge on Wednesday threw out a medical supply company's suit over COVID-19 test kit profits based on the Chinese citizenship of one party, adding that the plaintiff's impatience with the court amid a judge shortage was "rude." 
- 
									October 02, 2025
									Peach State Panel Tosses $500K Verdict In Peach Picking SpatThe Georgia Court of Appeals ordered a new trial in a case where a jury awarded $500,000 worth of punitive damages to a peach grower who said his crop was ruined by another farmer, ruling that inadmissible evidence about their settlement talks was "likely significant" in securing the verdict. 
- 
									October 02, 2025
									AstraZeneca Asks Judge To Block Colorado's 340B Drug LawAstraZeneca urged a Colorado federal judge on Wednesday to block the enforcement of a recently enacted state law that aims to extend a federal drug discount program to certain pharmacies, saying the Colorado law is costly for manufacturers and preempted by federal law. 
- 
									October 02, 2025
									Bain Inside Trade Claims Advance In Del. Cerevel Sale SuitDelaware's Court of Chancery on Thursday kept alive a pension funds suit alleging that private equity firm Bain Capital Investors LLC and others traded on inside information in the run-up to a secondary sale ahead of biopharmaceutical venture Cerevel Therapeutics Holdings Inc.'s $8.7 billion acquisition by AbbVie. 
Expert Analysis
- 
								
								Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling  The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law. 
- 
								
								Breaking Down The Proposed Hemp Bill  A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding. 
- 
								
								Assessing Federal Securities Class Action Stats In '25 So Far  The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group. 
- 
								Series Quilting Makes Me A Better Lawyer  Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham. 
- 
								
								How Agentic AI Is Testing The Limits Of Patent Law  While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein. 
- 
								
								How To Prep For Potential Passage Of SAFER Banking Act  The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard. 
- 
								
								A Former PTAB Judge Weighs The End Of Remote Hearings  Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime. 
- 
								
								The Future Of Lab-Test Regs After FDA Rescinds Rule  The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable. 
- 
								
								SDNY Ruling Reinforces Joint Steering Committee Obligations.jpg)  The recent Southern District of New York decision in ChemImage v. Johnson & Johnson makes joint steering committees a valuable tool in strategic relationships, as provisions for such committees can now be wielded to demand attention to core issues, say Lisa Bernstein at the University of Chicago Law School, and Reginald Goeke and Brad Peterson at Mayer Brown. 
- 
								
								What 2 Profs Noticed As Transactional Law Students Used AI  After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School. 
- 
								
								What Patent Claim 'Invalidity' Means In Different Forums  A recent Federal Circuit order allowing a patent suit to proceed despite similar claims being invalidated in an inter partes review underscores how fractured the patent litigation landscape has become, leading to critical nuances in how district courts, the U.S. International Trade Commission and Patent Trial and Appeal Board treat invalidity, says Jason Hoffman at BakerHostetler. 
- 
								Rebuttal BigLaw Settlements Should Not Spur Ethics Deregulation  A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project. 
- 
								
								How Big Pharma Has Responded To FTC Delisting Demands  Looking at some statistics concerning how pharmaceutical companies have responded to the Federal Trade Commission's recent challenges to Orange Book listings raises several possible hypotheses about the FTC's strategy and effectiveness, say Ratib Ali and Celia Lu at Competition Dynamics. 
- 
								
								5 Ways Lawyers Can Earn Back The Public's Trust  Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law. 
- 
								
								USPTO's AI Tool Redefines Design Patent Landscape  The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.